Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-J02 sacituzumab govitecan study in Japanese patients with advanced solid tumors
jRCT2031210346Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), breast cancer and 1 more (4 arms), sponsored by Gilead Sciences. Primary endpoints: Treatment-emergent adverse events, Laboratory abnormalities and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)breast cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031210346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210346.